Tau Conference from 5-9 March 2024TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), announced today that the company will present the 24-month data from its Phase III LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the upcoming AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference from 5-9 March 2024, in Lisbon, Portugal.
Look at Dundee stock trade volumes during conference. March 7 was press release.
Date | Mar 4,2024 | Mar 5, 2024 | Mar 6, 2024 | Mar 7, 2024 | Mar 8, 2024 |
High | 0.78 | 0.84 | 0.84 | 0.84 | 0.89 |
Low | 0.76 | 0.8 | 0.8 | 0.81 | 0.86 |
Close | 0.78 | 0.83 | 0.81 | 0.82 | 0.89 |
vwap | 0.773 | 0.83 | 0.83 | 0.82 | 0.865 |
volume | 19,000 | 1,724,400 | 1,328,000 | 2,261,616 | 9,500 |
value | $14,685 | $1,431,750 | $1,101,980 | $1,854,555 | $8,215 |
Notice anything?